Liquidia rockets 42% as $380.7M deal ends United Therapeutics legal battle
Liquidia's shares surged 42% after resolving its legal dispute with United Therapeutics through a $380.7M settlement.
As of October 14, 2026, the price remains at the close of 33.94, which is above the support level of 22.31, and the RSI stands at 18.3, indicating an oversold condition with potential for a rebound. Therefore, we consider a buy position, judging that there is room for upside toward the resistance level of 74.74.
If the current price reaches the resistance level of 74.74, I will take profit, and if it falls to the support level of 22.31, I will cut losses. These two prices are the resistance and support levels suggested by REPORTING, and amid the oversold condition with an RSI of 18.3, the resolution of legal risks provides upward momentum.
RSI(14) = 18.3 (oversold), moving averages not in proper alignment (trend unclear), volume = 0.84x of 20-day average (weak volume), 7-day volatility/rate of change = -6.4% (price decline)
The past case of LQDA (2026-10-15) is a directly similar case in that the same 'Liquidia' keyword and news of the resolution of legal disputes generated a 26.6% return, showing similarities in the current situation, news, and oversold indicators. VEEE (2026-07-16) and LRCX (2026-07-06) recorded large returns on news of a merger announcement and a tech stock surge, respectively, but are used only for reference as their direct keyword and industry relevance are low.
The forecast expected a 4.5% increase, but the actual return significantly outperformed at 26.6%. The purchase was made by capturing positive catalysts such as oversold RSI and the resolution of legal risks. While the target price and stop-loss settings were appropriate, the magnitude of the price increase was heavily underestimated. The stop-loss line was never reached.
Going forward, we will place greater weight on the impact of legal and regulatory news on the stock price, and scale up position sizes when the RSI falls below 20. At the same time, we will re-evaluate entry timing when trading volume is below average, and continuously monitor SEC filings, such as insider sales, to identify risks early.